Relmada Therapeutics (RLMD) Treasury Shares (2016 - 2026)

Relmada Therapeutics (RLMD) has 7 years of Treasury Shares data on file, last reported at $8.0 million in Q1 2026.

• Quarterly Treasury Shares rose 817.41% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (up 817.41% YoY) and the FY2025 annual result came in at $5.9 million, up 325.29% from the prior year.
• Treasury Shares climbed to $8.0 million in Q1 2026 per RLMD's latest filing, from $5.9 million in the prior quarter.
• Across five years, Treasury Shares topped out at $8.0 million in Q1 2026 and bottomed at $750908.0 in Q2 2025.
• The 5-year median for Treasury Shares is $1.7 million (2024), against an average of $2.7 million.
• The widest annual swing landed in 2025, when Treasury Shares plunged 54.86%; it then soared 817.41% in 2026.
• Tracing RLMD's Treasury Shares over 5 years: stood at $3.0 million in 2022, then dropped by 21.34% to $2.4 million in 2023, then sank by 41.94% to $1.4 million in 2024, then soared by 325.29% to $5.9 million in 2025, then jumped by 36.19% to $8.0 million in 2026.
• Per Business Quant, the three latest RLMD Treasury Shares figures stand at $8.0 million (Q1 2026), $5.9 million (Q4 2025), and $750908.0 (Q3 2025).

Peer Comparison